Yeon Hee Park
성균관대학교 의과대학 · 의학
Yeon Hee Park 교수의 연구실은 고도화된 분자 생물학적 분석을 기반으로 한 유방암 치료 전략 개발에 초점을 맞추고 있습니다. 특히 신선한 종양 생검을 통한 전장 전사체 분석과 종양 돌연변이 부담(TMB) 분석을 통해 환자별 맞춤형 치료 반응을 예측하고, HER2 양성 전이성 유방암에서의 저항성 메커니즘과 새로운 표적치료제의 유효성을 평가하고 있습니다. 임상 연구와 기초 연구를 융합한 전임상-임상 연계 연구가 특징입니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
To elucidate the effects of neoadjuvant chemotherapy (NAC), we conduct whole transcriptome profiling coupled with histopathology analyses of a longitudinal breast cancer cohort of 146 patients including 110 pairs of serial tumor biopsies collected before treatment, after the first cycle of treatment and at the time of surgery. Here, we show that cytotoxic chemotherapies induce dynamic changes in the tumor immune microenvironment that vary by subtype and pathologic response. Just one cycle of tre
This study explored the clinical implications of tumor mutational burden (TMB) in a well-defined HER2-positive metastatic breast cancer (MBC) patient population who had been previously treated but had subsequent disease progression. Whole exome sequencing was performed on formalin-fixed paraffin-embedded tumor samples and matched normal tissue. Among the 46 patients, 13 (28.3%) were estrogen receptor-positive and nine (19.6%) were progesterone receptor-positive by immunohistochemistry analysis.
ClinicalTrials.gov, NCT03401359. The trial was posted on 18 January 2018 and registered prospectively.
Although the introduction of human epidermal growth factor receptor (HER)2-directed therapy including trastuzumab, pertuzumab, lapatinib and trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancers (mBCs) favorably changed the natural history of this disease, most cases of HER2-positive mBC will eventually progress. Poziotinib is an oral pan-HER kinase inhibitor showing potent activity through irreversible inhibition of these kinases. This open-label, multicenter
ClinicalTrials.gov Identifier: NCT03881878.
